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Fragile X-associated disorders caused by the premutation of the FMR1
gene, includes the fragile X-associated tremor/ataxia syndrome (FXTAS).
FXTAS affects more than 40% of premutation males over the age of 50
and 75% over the age of 80. FMR1 molecular analysis was done using
PCR and confirmed by Southern Blot. Three premutation males were
diagnosed FXTAS using quantification based on the standard neurological
examination. Cognitive impairment was assessed using Raven and
WAIS-R test. MRI was done to identify the middle cerebellar peduncle
(MCP) sign, white matter disease and/or cerebral atrophy. Three cases of
FXTAS are identified, of five individuals older than 50 years in one family
tree two met criteria for definite FXTAS and the third with sub-clinical
symptoms, although cognitive and radiological criteria are met. These
cases are the first identified FXTAS cases in rural Indonesia. In addition
with lack of routine medical follow-up, complications of FXTAS, such as
hypertension may go unrecognized and untreated, which may further
exacerbate the central nervous system (CNS) findings of FXTAS.
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Premutation FMR-1 carriers are at risk of the fragile
X-associated tremor ataxia syndrome (FXTAS) (1), a
progressive late-adult-onset neurodegenerative disorder,
that occurs in approximately 40% of males (2) and
16.5% of females older than 50 years (3). Premutation
alleles of the FMR1 gene are frequent in general
population with a prevalence of 1:178 in females and
1:400 in males (4).
A two- to eightfold elevation of the FMR1 mRNA is
found in premutation carriers (5), leading to a toxic gain
of function mechanism that causes FXTAS (6). The
FMR1 mRNA toxicity in the brain will lead to neuronal
cell dysregulation and eventually intranuclear inclusion
formation in neurons and astrocytes throughout the
brain (7). The penetrance of FXTAS was found much
greater in mid-large sized premutations (70–200 CGG
repeats) compared to small premutation size (55–69
CGG repeats) (2, 8, 9). The higher the number of CGG
repeats, the greater the number of inclusions and the
earlier the onset of death, (10) though molecular studies
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in knock-in mice showed very few and small inclusion
formation with CGG repeat length exceeding 150 (11).
On the basis of frequency of midsized (≥70 CGG
repeats) premutation alleles, FXTAS is estimated to
occur in 1:4848 in the general population (12). The
most common clinical characteristics of FXTAS are
intention tremor, gait ataxia, and parkinsonism in
addition to neuropathy, cognitive decline and psycho-
logical symptoms of mood, and/or anxiety disorders
(13, 14). Magnetic resonance imaging (MRI) studies
demonstrate global brain atrophy and white matter
T2 hyperintensities in the middle cerebellar peduncles
(MCP), the pons, periventricular areas and subcortical
areas (15). A major criterion of FXTAS is white matter
disease in the MCP sign but this is found only in 58%
and 13% of affected males and females, respectively
(15). Premutation carriers who have intention tremor
and ataxia without any imaging anomalies will be
diagnosed as probable FXTAS. Those who have core
symptoms of intention tremor and/or ataxia with the
major radiological finding of the MCP sign will be
diagnosed as definite FXTAS (14).
So far, no Indonesian FXTAS case has been pub-
lished. This study was performed to identify potential
FXTAS patients in known FXS family pedigrees. Treat-
ment for symptoms of FXTAS is available in Indonesia,
so the identification of FXTAS is essential (16, 17).
Methods
Samples were obtained from a large family with
cases of FXS and positive samples were confirmed by
Southern blot. All family members signed an informed
consent. The following neurological assessment was
carried out in premutation over 50 years of age.
The mini mental state examinations (MMSE) was
used to screen memory and cognitive function followed
by Raven test for cultural and education free cognitive
assessment, then the WAIS-R was done for verbal and
nonverbal IQ, full scale IQ and short-term memory.
Average category according to Raven is percentile
range 26th–74th/Grade III (18) and for the Wechsler
is IQ range ≥90 (19). MRI was carried out to assess
cerebral atrophy and white matter disease. A physical
and neurological examination was completed by
a neurologist and the examination was videotaped
for further assessment by blinded examiners. This
examination included the following:
1 Quantification of the tremor
The most common method of measuring tremor
is finger-to-nose testing (20), and combined with
functional performance tests included picking up a
coin and pouring water. Fahn tremor rating (FTR)
scale was used to quantify tremor (21).
2 Quantification of the ataxia
Ataxia quantification was adapted from Notermans et
al. (22) and combined with the gait and balance scale
(GABS) (23). Ataxia testing included (i) tapping
test for upper and lower extremities; (ii) quantitative
finger-to-nose testing; (iii) quantitative Romberg
test; (iv) tandem walk; and (v) postural stability
response to sudden posterior displacement by pull
on shoulders while patient is erect and alert. Tapping
test was done with both dominant and non-dominant
upper and lower extremities, scaled quantitatively by
using mean result (22) and Modified International
Cooperative Ataxia Rating Scale (MICARS) (24).
Results
All premutation individuals of one large fragile X
family (Fig. 1) older than 50 years were assessed
(N = 5; four male and one female). Three cases of
FXTAS were identified, two met criteria for definite
FXTAS and the third had sub-clinical symptoms
although cognitive and radiological criteria were met.
The main neurological features of FXTAS and other
common medical conditions were observed among all
cases (Table 1). MRI imaging was abnormal in all three
cases (Fig. 2) The cognitive function test results are
presented in Table 2.
Case reports
Case 1 is a 74-year-old male with a premutation of
88 CGG repeats. For the last 3 years he worked less
Fig. 1. Pedigree of the fragile X-associated tremor ataxia (FXTAS) family. Arrows indicate the affected individuals. Pedigree number III.7 is
case 1 and III.12 is case 2 who were diagnosed definite FXTAS. Pedigree number III.14 is case 3 who was diagnosed sub-clinical FXTAS although
cognitive deficits and radiological signs were not subclinical.
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Table 1. Clinical symptoms and other medical conditions among premutation male cases
Case 1: a 74-year-old male
premutation carrier (88 CGG repeats)
Case 2: a 70-year-old male
premutation carrier (104 CGG repeats)
Case 3: a 68-year-old male
premutation carrier (110 CGG repeats)
Neurological symptoms
Quantitative tremor:
1. Finger to nose: slight/intermittent
tremor (1)
2. Pick up coin (1)
3. Pouring water (spills < 10%/2)
Quantitative tremor:
1. Finger to nose: no tremor (0)
2. Pick up coin (0)
3. Pouring water (spills < 10%/2)
Quantitative tremor:
1. Finger to nose: no tremor (0)
2. Pick up coin (0)
3. Pouring water (0)
Quantitative ataxia:
1. Upper and lower limb tapping (2)
2. Finger to nose (open and closed
eyes): 0 cm
3. Heel to toe Romberg test with
eyes closed (failed/4)
4. Tandem walk: unable/2
5. Postural stability test (absence/3)
Quantitative ataxia:
1. Upper and lower limb tapping (1)
2. Finger to nose (open and closed
eyes): 0 cm
3. Heel to toe Romberg test with
eyes closed (5–10 second/2)
4. Tandem walk: impaired/1
5. Postural stability test (retropulsion
recovers unaided/2)
Quantitative ataxia:
1. Upper and lower limb tapping (1)
2. Finger to nose (open and closed
eyes): 0 cm
3. Heel to toe Romberg test with
eyes closed (5–10 second/2)
4. Tandem walk: normal/0
5. Postural stability test: normal
Dysdiadochokinesis: positive using
cane for 2 years
Dysdiadochokinesis: positive Dysdiadochokinesis: none
Other medical conditions
1. Hypertension (190/130 mmHg)
2. Hearing impairment
3. Peripheral neuropathy
1. Hypertension (150/100 mmHg)
2. Hearing impairment
3. Peripheral neuropathy
1. Hypertension (160/100 mmHg)
2. Hearing impairment
(a)
(b) (c)
Fig. 2. Radiological imaging of three premutation males. Solid arrow shows middle cerebellar peduncle (MCP) sign, dashed arrow indicate
cerebral atrophy, and dotted arrow indicates white matter disease. Radiological imaging case 1 shows obvious MCP sign, severe cerebral atrophy,
and extensive white matter disease in cerebrum (a); case 2 shows moderate MCP sign, moderate cerebral atrophy, and limited white matter disease
(b); case 3 shows remarkable MCP sign, mild cerebral atrophy, and limited white matter disease (c).
frequently and effectively as a farmer compared to his
peers and at 72, he fell off a ladder and used a cane
ever since because of instability in walking (ataxia).
Cognitive impairment has been reported by his family,
especially short-term memory problems. The MCP sign
and significant cerebral atrophy was found on MRI and
because of tremor and ataxia on examination he was
diagnosed with definite FXTAS. He had hypertension,
hearing impairment and numbness, tingling and burning
of feet, which were all documented on examination
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Table 2. Cognitive function test result of male premutation cases
Case Formal education Cognitive function
Case 1 Second grade of elementary school MMSE test: N/A
Raven test: <5th percentile
WAIS-R results:
- Verbal IQ = 99
- Non-verbal IQ = 93
- Full IQ = 89 (low average)
- Digit span/short-term memory = 5 (very low)
Case 2 First grade of elementary school MMSE test: 15 (definite cognitive impairment)
Raven test: <5th percentile
WAIS-R results:
- Verbal IQ = 71
- Non-verbal IQ = 69
- Full IQ = 68 (mild mental retardation)
- Digit span/short term memory = 2 (very low)
Case 3 No formal education MMSE test: 27 (normal)
Raven test: <5th percentile
WAIS-R results:
- Verbal IQ = 84
- Non-verbal IQ = 75
- Full IQ = 71 (borderline)
- Digit span/short-term memory = 6 (low)
MMSE, mini mental state examination; N/A, not available.
(Table 1). He has three sons and three daughters. His
first daughter has three children with FXS (one boy,
two girls).
Case 2 is a 70-year-old male farmer with a premu-
tation of 104 CGG repeats. His family recognized his
cognitive decline 5 years ago and it became particularly
problematic over the last 2 years with short-term mem-
ory problems interfering with daily activities. Hyperten-
sion, hearing impairment and also numbness, tingling
and burning feet had been self-reported. He has two
daughters and one son, and healthy grandchildren. His
examination is outlined in Table 1. He is diagnosed
with definite FXTAS and cognitive impairment consis-
tent with dementia and severe hypertension. His MRI
showed the MCP sign and significant brain atrophy
(Fig. 2).
Case 3 is a 68-year-old male farmer with a premuta-
tion of 110 CGG repeats. He complained of cognitive
decline beginning 3 years ago, but he is still managing
financial matters. Hypertension and hearing impairment
had been self-reported. His examination was docu-
mented in Table 1; he did not demonstrate tremor and
ataxia. Surprisingly, MRI showed a noticeable MCP
sign with additional white matter disease. He had cog-
nitive impairment, with Raven test <5th percentile and
very low short-term memory test. He has two sons and
one granddaughter. His diagnosis is FXTAS presenting
with cognitive impairment and severe hypertension but
without significant tremor and ataxia.
Discussion
We report the first three cases of FXTAS in Indonesia.
Progression is age dependent with the oldest affected
the most and the youngest the least. There is also a
similar pattern of symptom progression: hypertension,
cognitive decline and then tremor and ataxia. Cellular
studies showed that the threshold for toxicity lies
between 62 and 95 CGG repeats, and sizes of 95
CGGs and above have an inverse correlation between
FMR1 mRNA concentration and cell viability (25).
The CGG repeat lengths reported in our cases ranged
from 88 to 110 repeats, the youngest one carrying
110 repeats with the mildest clinical phenotype but the
earliest onset. All three cases had obvious cognitive
impairment.
Inability to tandem walk is perhaps the best clinical
measure to detect ataxia as previously described, and
it is the main clinical sign of FXTAS (14, 26). Case 3
had no significant tremor or ataxia but presented with
cognitive impairment and radiological signs of FXTAS.
A similar phenotype is also reported in rural France
(9). Cognitive impairment may be more obvious among
people with a low socio-economic and education status
and may precede symptoms of tremor and ataxia. All
three cases reported here had significant MRI involve-
ment including the MCP sign, brain atrophy and exten-
sive white matter disease. Radiological involvement
could be exacerbated by the severe untreated hyperten-
sion which is part of the autonomic dysfunction associ-
ated with the premutation and more common in FXTAS
(27, 28). Similar to case 3, the MCP sign without
tremor or ataxia has been reported before in premutation
carriers (29) and early brain structural and anatomi-
cal abnormalities may occur before the clinical onset
of FXTAS (30).
Cognitive impairment is seen in the majority of
patients with FXTAS including memory and executive
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function deficits (31). However, dementia is seen only
in approximately 50% of male patients with FXTAS
(32). Our FXTAS cases had cognitive measures consis-
tent with dementia. However, lack of education, liv-
ing in a rural environment with manual labor does
not provide the intellectually stimulating environment,
which could counteract cognitive decline. In addi-
tion, their hypertension may have exacerbated cog-
nitive decline. In rural France, the relative risk to
develop cognitive impairment among males with lit-
tle education and mid-large size premutation alleles
(70–200 CGG repeat) and small premutation alle-
les (55–69 CGG repeats) was estimated 6.5 and 1.1,
respectively, at age 63.5 years compared to controls
(9). Hearing loss seen in all three cases and pre-
viously reported in FXTAS (2) may also contribute
to cognitive impairment because of lack of auditory
stimulation.
Conclusions
FXTAS cases are found in the Indonesian FXS family.
Screening for FXTAS is an important endeavor for
professionals who see families with FXS in poor
countries where access to medical care is less than
optimal. Treatments are available for many of the
symptoms of FXTAS including tremor, ataxia, neu-
ropathy, chronic pain, hypertension, hypothyroidism
and parkinsonism (16, 28, 33). Early treatment
of hypertension may slow progression of radio-
logical changes and cognitive decline leading to
dementia.
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